Abstract
Elevated levels of Low Density Lipoprotein cholesterol (LDL-C) are directly associated with increased risk for atherosclerotic cardiovascular and cerebrovascular events. Statins have been used to control serum LDLC and this has translated into reduction in cardiovascular and cerebrovascular events. However, despite high dose statin therapy, LDL-C control may remain inadequate in some patients, particularly those with familial hypercholesterolemia. A new therapeutic approach has emerged in recent years with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.
In this review, we describe the development and the use of this new class of drugs.
Keywords: Cholesterol, LDL, PCSK9 inhibitors, statins, serum LDL-C, hypercholesterolemia.
Current Pharmaceutical Design
Title:Proprotein Convertase Subtilisin/kexin type 9 Inhibition in Cardiovascular Prevention
Volume: 24 Issue: 4
Author(s): Ali Ali, Pierluigi Costanzo and Angela Hoye*
Affiliation:
- Department of Academic Cardiology, University of Hull, Kingston upon Hull,United Kingdom
Keywords: Cholesterol, LDL, PCSK9 inhibitors, statins, serum LDL-C, hypercholesterolemia.
Abstract: Elevated levels of Low Density Lipoprotein cholesterol (LDL-C) are directly associated with increased risk for atherosclerotic cardiovascular and cerebrovascular events. Statins have been used to control serum LDLC and this has translated into reduction in cardiovascular and cerebrovascular events. However, despite high dose statin therapy, LDL-C control may remain inadequate in some patients, particularly those with familial hypercholesterolemia. A new therapeutic approach has emerged in recent years with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.
In this review, we describe the development and the use of this new class of drugs.
Export Options
About this article
Cite this article as:
Ali Ali , Costanzo Pierluigi and Hoye Angela *, Proprotein Convertase Subtilisin/kexin type 9 Inhibition in Cardiovascular Prevention, Current Pharmaceutical Design 2018; 24 (4) . https://dx.doi.org/10.2174/1381612824666180111105201
DOI https://dx.doi.org/10.2174/1381612824666180111105201 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacotherapy Before and After Endovascular Repair of Abdominal Aortic Aneurysms
Current Vascular Pharmacology Virus Vasculopathy and Stroke: An Under-Recognized Cause and Treatment Target
Infectious Disorders - Drug Targets Predementia and Dementia Syndromes: Possible Role of Lipoprotein Metabolism
Vascular Disease Prevention (Discontinued) Creutzfeldt-Jakob, Parkinson, Lewy Body Dementia and Alzheimer Diseases: From Diagnosis to Therapy
Central Nervous System Agents in Medicinal Chemistry Sphingosine 1-Phosphate in Vascular Biology: Possible Therapeutic Strategies to Control Vascular Diseases
Current Pharmaceutical Design Predictors of Conversion to Dementia of Probable Alzheimer Type in Patients with Mild Cognitive Impairment
Current Alzheimer Research Modulation of Retinal Arteriolar Central Reflection by APOE Genotype
Current Alzheimer Research Assessing Activation States in Microglia
CNS & Neurological Disorders - Drug Targets Inflammatory Process in Alzheimer’s and Parkinson's Diseases: Central Role of Cytokines
Current Pharmaceutical Design Novel Inflammatory Markers in Hyperlipidemia: Clinical Implications
Current Medicinal Chemistry CGRP and CGRP-Receptor as Targets of Migraine Therapy: Brain Prize-2021
CNS & Neurological Disorders - Drug Targets The Stroke-Induced Blood-Brain Barrier Disruption: Current Progress of Inspection Technique, Mechanism, and Therapeutic Target
Current Neuropharmacology Subduing the Green-eyed Monster: Bridging the Psychopharmacological and Psychosocial Treatment Perspective in Understanding Pathological Jealousy
Current Drug Targets Obstructive Sleep Apnea Syndrome: An Emerging Risk Factor for Dementia
CNS & Neurological Disorders - Drug Targets Aromatase Inhibitors: A New Reality for the Adjuvant Endocrine Treatment of Early-Stage Breast Cancer in Postmenopausal Women
Mini-Reviews in Medicinal Chemistry Protein Misfolding in Disease: Cause or Response?
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Evaluation of Common Unfavourable Genetic Variants in Cerebrovascular Diseases: Recommendation for Supportive Genetic Examinations and Methodological Approaches for Common Genetic Variants
Current Medicinal Chemistry Direct and Indirect Measurement of Temporal Horn Volume and Temporal Horn Index and its Neuropsychological Correlation in Mild Cognitive Impaired and Alzheimer Diseased Patients
Current Medical Imaging Acute Stroke Therapy: Combination Drugs and Multifunctional Neuroprotectants
Current Neuropharmacology Editorial: Current Vision of Systemic Autoimmune Diseases - From Diagnosis to Management
Endocrine, Metabolic & Immune Disorders - Drug Targets